Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Income from Continuing Operations (2020 - 2025)

Lyell Immunopharma's Income from Continuing Operations history spans 5 years, with the latest figure at 33987000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 23.69% year-over-year to 33987000.0; the TTM value through Sep 2025 reached 327583000.0, down 71.61%, while the annual FY2024 figure was 334687000.0, 49.71% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 33987000.0 at Lyell Immunopharma, up from 43864000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 11331000.0 in Q4 2022 and bottomed at 196227000.0 in Q4 2024.
  • The 5-year median for Income from Continuing Operations is 52424000.0 (2023), against an average of 57011263.16.
  • The largest annual shift saw Income from Continuing Operations soared 76.0% in 2022 before it plummeted 362.66% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 47215000.0 in 2021, then skyrocketed by 76.0% to 11331000.0 in 2022, then crashed by 362.66% to 52424000.0 in 2023, then plummeted by 274.31% to 196227000.0 in 2024, then soared by 82.68% to 33987000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Income from Continuing Operations are 33987000.0 (Q3 2025), 43864000.0 (Q2 2025), and 53505000.0 (Q1 2025).